Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed
Filament Health (NEO: FH) has announced a merger that would see it listed on the NASDAQ exchange. The agreement would merge Filament with Jupiter Acquisition Corporation (NASDAQ: JAQC), a special purpose acquisition vehicle (SPAC).
“Today’s announcement is an important milestone for Filament as we gain access to the broader capital markets needed to advance our drug development platform,” said Ben Lightburn, CEO.
“We are highly encouraged by the Phase 1 study observations and results, which give us confidence in selecting doses of BMB-101 for testing in refractory epilepsies and other disorders where serotonin 2C agonists are indicated. Learnings from the study will inform our path forward as we seek to develop effective therapeutic options with convenient dosing regimens for patients,” stated Mark A. Smith, M.D., Ph.D., Chief Medical Officer of Bright Minds.
Results from a phase 3 trial show that generic ketamine was safe and effective in treating patients with treatment-resistant depression.
The double-blind, randomized, active-controlled multicentre trial was conducted at seven mood disorders centres in Australia and New Zealand. Results were published in The British Journal of Psychiatry and online in the Cambridge University Press.
Enveric Biosciences Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373
Absorption, distribution, metabolism, and excretion (ADME) and toxicology assays demonstrated rapid conversion of EB-373 to the active metabolite psilocin, consistent with previously reported animal pharmacokinetic (PK) studies.
“These ADME and toxicology data help us further understand and confirm our molecular design success as we seek to harness the neuroplastogenic properties of psilocin while offering a potential treatment that better controls the hallucinatory effects in humans,” said Joseph Tucker, Ph.D., Director and CEO of Enveric. “With these in vitro analyses, in addition to our animal PK studies, we are building a robust pharmaceutical profile as we progress EB-373 to human testing in clinical trials.”
The company successfully completed a research study evaluating PharmaPatch, a proprietary microneedle patch, in delivering N,N-dimethyltryptamine (“DMT”). The research study was conducted with Terasaki Institute for Biomedical Innovation (“Terasaki”).
A DMT PharmaPatch may enable an effective microdosing delivery solution and potential flexible drug load capacity and combinations, controlled released delivery, and be able to present desired pharmacokinetic and safety profiles, which could potentially overcome obstacles associated with oral and intravenous dosing.